← All trials
NCT07187141
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2021
- Primary completion
- Sep 22, 2022
- Completion date
- Feb 21, 2023
- First posted
- Sep 22, 2025
- Last posted
- Sep 22, 2025
- Enrollment
- 16
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversitySponsor investigator
- I-Mab BiopharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.